MetaVia logo
MetaVia
MTVA | NASDAQ
Chart Builder DCF Calculator
$1.21
-$0.09 (-6.92%)
At close: Nov 16, 2026, 4:00 PM ET
$1.29
+$0.08 (+6.61%)
After-hours: Nov 16, 2026, 7:48 PM ET

MetaVia Company Profile

Company profile explained

Company Profile

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

Key Executives

Name Position
Hyung-Heon Kim Chief Executive Officer, President & Director
Marshall H. Woodworth Chief Financial Officer
Mi-Kyung Kim Chief Scientific Officer
Michael C. Pine Senior Vice President of Business Development Advisor
Robert Homolka Senior Vice President of Clinical Operations
W. Christopher Fang Consulting Chief Medical Officer & Advisor

Latest SEC Filings

Date Type Title
Oct 28, 2026 8-K Current Report
May 27, 2026 8-K Current Report
May 18, 2026 8-K Current Report
May 15, 2026 SC 13G Statement of acquisition of beneficial ownership b...
May 14, 2026 10-Q Quarterly Report
May 14, 2026 8-K Current Report
May 11, 2026 8-K Current Report
Apr 27, 2026 ARS Filing
Apr 27, 2026 DEF 14A Filing
Apr 15, 2026 PRE 14A Filing
View All SEC Filings ➞
MetaVia
MetaVia logo
Country United States
IPO Date Aug 5, 2016
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Hyung Heon Kim

Contact Details

545 Concord Avenue Cambridge, Massachusetts 02138 United States

Stock Details

Ticker Symbol MTVA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001638287
CUSIP Number 64132R503
ISIN Number US64132R5037
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.